A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Participation Deadline: 09/14/2027
Apply Now

Description

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.

The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.

A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.

The expected trial duration per participant is approximately 86 weeks.